S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
EXPLAINER: What's the effect of Russian oil price cap, ban?
MarketBeat: Week in Review 11/28 – 12/02
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
EXPLAINER: What's the effect of Russian oil price cap, ban?
MarketBeat: Week in Review 11/28 – 12/02
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
EXPLAINER: What's the effect of Russian oil price cap, ban?
MarketBeat: Week in Review 11/28 – 12/02
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
EXPLAINER: What's the effect of Russian oil price cap, ban?
MarketBeat: Week in Review 11/28 – 12/02
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Rail workers say deal won't resolve quality-of-life concerns
NASDAQ:AXGN

AxoGen - AXGN Stock Forecast, Price & News

$11.09
+0.06 (+0.54%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.89
$11.13
50-Day Range
$10.40
$13.09
52-Week Range
$6.87
$13.66
Volume
106,523 shs
Average Volume
312,973 shs
Market Capitalization
$469.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

AxoGen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
44.3% Upside
$16.00 Price Target
Short Interest
Healthy
1.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$126,510 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

435th out of 1,034 stocks

Electromedical Equipment Industry

7th out of 23 stocks

AXGN stock logo

About AxoGen (NASDAQ:AXGN) Stock

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AXGN Stock News Headlines

AxoGen, Inc. (AXGN)
Axogen: Q2 Earnings Insights - Benzinga
See More Headlines
Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AXGN Company Calendar

Last Earnings
11/02/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXGN
Employees
428
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+44.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-26,990,000.00
Pretax Margin
-21.51%

Debt

Sales & Book Value

Annual Sales
$127.36 million
Book Value
$2.40 per share

Miscellaneous

Free Float
39,111,000
Market Cap
$469.00 million
Optionable
Optionable
Beta
0.49

Key Executives

  • Ms. Karen ZaderejMs. Karen Zaderej (Age 60)
    Chairman, Pres & CEO
    Comp: $1.16M
  • Mr. Peter J. Mariani (Age 58)
    Exec. VP & CFO
    Comp: $696.4k
  • Ms. Maria D. MartinezMs. Maria D. Martinez (Age 54)
    Chief HR Officer
    Comp: $498.62k
  • Mr. Angelo G. Scopelianos Ph.D. (Age 67)
    Chief R&D Officer
    Comp: $613.99k
  • Mr. Michael Donovan (Age 57)
    VP of Operations
  • Ed Joyce
    Director of Investor Relations
  • Mr. Bradley L. Ottinger J.D. (Age 52)
    Gen. Counsel & Chief Compliance Officer
  • Mr. Gregory Davault (Age 54)
    VP of Marketing
  • Ms. Doris Quackenbush
    VP of Sales
  • Ms. Isabelle Billet (Age 60)
    Chief Strategy & Bus. Devel. Officer













AXGN Stock - Frequently Asked Questions

Should I buy or sell AxoGen stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings
or view top-rated stocks.

What is AxoGen's stock price forecast for 2023?

3 equities research analysts have issued 12 month price targets for AxoGen's stock. Their AXGN share price forecasts range from $15.00 to $18.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 44.3% from the stock's current price.
View analysts price targets for AXGN
or view top-rated stocks among Wall Street analysts.

How have AXGN shares performed in 2022?

AxoGen's stock was trading at $9.37 on January 1st, 2022. Since then, AXGN stock has increased by 18.4% and is now trading at $11.09.
View the best growth stocks for 2022 here
.

When is AxoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our AXGN earnings forecast
.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) issued its earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. The medical equipment provider earned $31.20 million during the quarter, compared to analyst estimates of $34.65 million. AxoGen had a negative net margin of 21.51% and a negative trailing twelve-month return on equity of 18.09%. During the same quarter in the prior year, the company earned ($0.04) earnings per share.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $137.50 million-$140.00 million, compared to the consensus revenue estimate of $139.34 million.

What is Karen Zaderej's approval rating as AxoGen's CEO?

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (6.89%), BlackRock Inc. (6.87%), Point72 Asset Management L.P. (5.12%), Vanguard Group Inc. (4.51%), Perceptive Advisors LLC (2.25%) and State Street Corp (1.97%). Insiders that own company stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani.
View institutional ownership trends
.

How do I buy shares of AxoGen?

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $11.09.

How much money does AxoGen make?

AxoGen (NASDAQ:AXGN) has a market capitalization of $469.00 million and generates $127.36 million in revenue each year. The medical equipment provider earns $-26,990,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does AxoGen have?

The company employs 428 workers across the globe.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801.

This page (NASDAQ:AXGN) was last updated on 12/3/2022 by MarketBeat.com Staff